ATE208397T1 - Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe - Google Patents

Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe

Info

Publication number
ATE208397T1
ATE208397T1 AT96900215T AT96900215T ATE208397T1 AT E208397 T1 ATE208397 T1 AT E208397T1 AT 96900215 T AT96900215 T AT 96900215T AT 96900215 T AT96900215 T AT 96900215T AT E208397 T1 ATE208397 T1 AT E208397T1
Authority
AT
Austria
Prior art keywords
aryl substituted
nitro compounds
aromatic nitro
linked aromatic
inflammatory actives
Prior art date
Application number
AT96900215T
Other languages
English (en)
Inventor
Jacques Yves Gauthier
Cheuk K Lau
Yves Leblanc
Chun-Sing Li
Patrick Roy
Michel Therien
Zhaoyin Wang
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Application granted granted Critical
Publication of ATE208397T1 publication Critical patent/ATE208397T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT96900215T 1995-01-11 1996-01-10 Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe ATE208397T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/371,179 US5552422A (en) 1995-01-11 1995-01-11 Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
PCT/CA1996/000014 WO1996021667A1 (en) 1995-01-11 1996-01-10 Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents

Publications (1)

Publication Number Publication Date
ATE208397T1 true ATE208397T1 (de) 2001-11-15

Family

ID=23462829

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96900215T ATE208397T1 (de) 1995-01-11 1996-01-10 Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe

Country Status (9)

Country Link
US (1) US5552422A (de)
EP (1) EP0802917B1 (de)
JP (1) JPH11501902A (de)
AT (1) ATE208397T1 (de)
AU (1) AU697650B2 (de)
CA (1) CA2209895A1 (de)
DE (1) DE69616749T2 (de)
ES (1) ES2165969T3 (de)
WO (1) WO1996021667A1 (de)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4419315A1 (de) * 1994-06-01 1995-12-07 Merckle Gmbh Heteropyrrolizinverbindungen und deren Anwendung in der Pharmazie
DE4419247A1 (de) * 1994-06-01 1995-12-07 Merckle Gmbh Sulfonylierte Pyrrolizincarbonsäureamide und deren Anwendung in der Pharmazie
DE4419246A1 (de) * 1994-06-01 1995-12-07 Merckle Gmbh Heteroarylsubstituierte Pyrrolizinverbindungen und deren Anwendung in der Pharmazie
ES2203985T3 (es) * 1997-09-05 2004-04-16 Glaxo Group Limited Derivados de 2,3-diaril-pirazolo(1,5)piridazina, su preparacion y su uso como inhibidores de la ciclooxigenasa 2(cox-2)`.
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US6040450A (en) * 1997-09-25 2000-03-21 Merck & Co., Inc. Process for making diaryl pyridines useful as cox-2-inhibitors
FR2770131A1 (fr) * 1997-10-27 1999-04-30 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
FR2771005B1 (fr) * 1997-11-18 2002-06-07 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
US7041694B1 (en) 1997-12-17 2006-05-09 Cornell Research Foundation, Inc. Cyclooxygenase-2 inhibition
DK1685839T3 (da) 1997-12-22 2013-06-24 Euro Celtique Sa Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
CN1263755C (zh) 1998-11-03 2006-07-12 葛兰素集团有限公司 作为选择性cox－2抑制剂的吡唑并吡啶衍生物
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
ATE261444T1 (de) * 1999-02-27 2004-03-15 Glaxo Group Ltd Pyrazolopyridine
EA008242B1 (ru) * 1999-12-08 2007-04-27 Фармация Корпорейшн Композиции на основе ингибитора циклооксигеназы-2 с быстро наступающим терапевтическим действием и способы лечения заболеваний
GB9930358D0 (en) 1999-12-22 2000-02-09 Glaxo Group Ltd Process for the preparation of chemical compounds
DE10004157A1 (de) 2000-02-01 2001-08-02 Merckle Gmbh Chem Pharm Fabrik 4-Pyridyl-und 2,4-Pyrimidinyl-substituierte Pyrrolderivate und ihre Anwendung in der Pharmazie
PL357158A1 (en) 2000-02-08 2004-07-12 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
AU776666B2 (en) 2000-02-08 2004-09-16 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
AU5754701A (en) * 2000-07-13 2002-01-30 Pharmacia Corp Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
WO2002024711A1 (en) * 2000-09-20 2002-03-28 Nikken Chemicals Co., Ltd. Novel thiazole bicyclic compounds
WO2002048148A2 (en) * 2000-12-15 2002-06-20 Glaxo Group Limited Pyrazolopyridine derivatives
ATE301653T1 (de) * 2000-12-15 2005-08-15 Glaxo Group Ltd Pyrazolopyridine
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
DE60201074T2 (de) * 2001-03-08 2005-09-15 Smithkline Beecham Corp. Pyrazolopyridinderivate
EP1372643A1 (de) * 2001-03-30 2004-01-02 Smithkline Beecham Corporation Pyrazolopyridine, verfahren zu ihrer herstellung und verwendung als therapeutika
EP1372642A1 (de) * 2001-03-30 2004-01-02 SmithKline Beecham Corporation Verwendung von pyrazolopyridinen als therapeutika
PE20021017A1 (es) 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
ITMI20010733A1 (it) 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
US7141569B2 (en) * 2001-04-10 2006-11-28 Smithkline Beecham Corporation Antiviral pyrazolopyridine compounds
ES2242028T3 (es) * 2001-04-27 2005-11-01 Smithkline Beecham Corporation Derivados de pirazolo(1,5-a)piridina.
US6756498B2 (en) 2001-04-27 2004-06-29 Smithkline Beecham Corporation Process for the preparation of chemical compounds
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
HUP0400266A2 (hu) * 2001-06-21 2004-08-30 Smithkline Beecham Corp. Imidazo[1,2-a]piridin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk herpeszvírus-fertőzések megelőzésére vagy kezelésére
US7943173B2 (en) 2001-07-18 2011-05-17 Purdue Pharma L.P. Pharmaceutical combinations of oxycodone and naloxone
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
WO2003013525A1 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
ATE364043T1 (de) * 2001-09-07 2007-06-15 Smithkline Beecham Corp Pyrazolo-pyridine für die behandlung von herpes- ansteckungen
WO2003031446A1 (en) * 2001-10-05 2003-04-17 Smithkline Beecham Corporation Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
AU2002357740A1 (en) * 2001-12-11 2003-06-23 Smithkline Beecham Corporation Pyrazolo-pyridine derivatives as antiherpes agents
CA2478515C (en) 2002-04-05 2010-09-28 Purdue Pharma Pharmaceutical preparation containing oxycodone and naloxone
WO2003088814A2 (en) 2002-04-17 2003-10-30 The Cleveland Clinic Foundation Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents
PT3072978T (pt) 2002-05-09 2018-10-15 Brigham & Womens Hospital Inc 1l1rl-1 como um marcador de doença cardiovascular
US7273616B2 (en) * 2002-05-10 2007-09-25 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagating Varicella zoster virus and methods of use thereof
US20040021778A1 (en) * 2002-08-05 2004-02-05 Oldani Jerome L. Security system with remote access and control
DK1551372T3 (en) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
JP2006504728A (ja) * 2002-10-03 2006-02-09 スミスクライン ビーチャム コーポレーション ピラソロピリジン誘導体系治療用化合物
EP1556083B1 (de) * 2002-10-08 2011-02-02 Rinat Neuroscience Corp. Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
EP2270048B1 (de) * 2002-12-24 2015-11-11 Rinat Neuroscience Corp. Anti-NGF Antikörper und Verfahren zu ihrer Verwendung
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
KR20050111598A (ko) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
EP1670459A4 (de) * 2003-08-20 2009-03-25 Nitromed Inc Nitrosierte und nitrosylierte kardiovaskuläre verbindungen, zusammensetzungen und anwendungsverfahren
JP2007504136A (ja) * 2003-08-28 2007-03-01 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化利尿化合物、組成物、ならびに使用方法
DK2384753T3 (en) 2003-08-29 2016-04-11 Brigham & Womens Hospital Hydantoin derivatives as inhibitors of cell necrosis
EP1663229B1 (de) 2003-09-25 2010-04-14 Euro-Celtique S.A. Pharmazeutische kombinationen von hydrocodon und naltrexon
KR100647583B1 (ko) * 2003-10-07 2006-11-17 삼성에스디아이 주식회사 이미다졸 고리 함유 화합물 및 이를 이용한 유기 전계발광 소자
WO2005044227A1 (en) * 2003-11-05 2005-05-19 Glenmark Pharmaceuticals Limited Topical pharmaceutical compositions
US20050100594A1 (en) * 2003-11-12 2005-05-12 Nilendu Sen Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
ATE546734T1 (de) 2003-12-05 2012-03-15 Cleveland Clinic Foundation Risikomarker für eine herzkreislaufkrankheit
US20090131342A1 (en) * 2004-01-22 2009-05-21 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
AU2005243247B2 (en) 2004-04-07 2012-03-01 Regents Of The University Of Minnesota Methods for treating bone cancer pain by administering a nerve growth factor antagonist
EP1604666A1 (de) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
EP1765292B1 (de) 2004-06-12 2017-10-04 Collegium Pharmaceutical, Inc. Gegen missbrauch gesicherte arzneimittelformulierungen
WO2006041855A2 (en) 2004-10-04 2006-04-20 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
CA2624601C (en) 2004-10-06 2018-07-03 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
WO2006052899A2 (en) * 2004-11-08 2006-05-18 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
US20080275093A1 (en) * 2004-11-15 2008-11-06 Nitromed, Inc. Diuretic Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use
CA2595579A1 (en) * 2005-01-21 2006-07-27 Nitromed, Inc. Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
EP1858525A2 (de) * 2005-02-16 2007-11-28 Nitromed, Inc. Organische stickoxidspendersalze antimikrobieller verbindungen, zusammensetzungen und verwendungsverfahren
WO2006093864A1 (en) * 2005-02-28 2006-09-08 Nitromed, Inc. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
WO2006099058A2 (en) * 2005-03-09 2006-09-21 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
CN102379684B (zh) 2005-04-28 2014-11-19 普罗透斯数字保健公司 药物信息系统
WO2006127591A2 (en) * 2005-05-23 2006-11-30 Nitromed, Inc. Organic nitric oxide enhancing salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
WO2007016677A2 (en) 2005-08-02 2007-02-08 Nitromed, Inc. Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
US20090054381A1 (en) * 2005-10-04 2009-02-26 Nitromed, Inc. Methods for treating respiratory disorders
US8119358B2 (en) 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
WO2007059311A2 (en) * 2005-11-16 2007-05-24 Nitromed, Inc. Furoxan compounds, compositions and methods of use
EP1968584A2 (de) * 2005-12-20 2008-09-17 Nitromed, Inc. Stickoxid-verstärkende glutaminsäure-verbindungen, zusammensetzungen und anwendungsverfahren
WO2007075542A2 (en) * 2005-12-22 2007-07-05 Nitromed, Inc. Nitric oxide enhancing pyruvate compounds, compositions and methods of use
EP3279663B1 (de) 2006-03-15 2021-07-28 The Brigham and Women's Hospital, Inc. Verwendung von gelsolin zur diagnose und behandlung von entzündungserkrankungen
CA2647859C (en) * 2006-03-29 2016-01-05 Nitromed, Inc. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
CA2659082A1 (en) 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
KR101486228B1 (ko) 2006-06-19 2015-01-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
KR20090071598A (ko) 2006-09-18 2009-07-01 랩터 파마슈티컬 인코포레이티드 수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료
BRPI0810409A2 (pt) 2007-04-18 2015-02-18 Thethys Bioscience Inc Biomarcadores relacionados ao diabetes e métodos de uso destes
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
EP2398500B1 (de) 2009-02-20 2019-03-13 2-BBB Medicines B.V. Arzneiabgabesystem auf glutathion-basis
WO2010103039A1 (en) 2009-03-10 2010-09-16 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
ES2942923T3 (es) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
FR2945289A1 (fr) * 2009-05-11 2010-11-12 Sanofi Aventis Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique
WO2011032175A1 (en) 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
TW201201764A (en) 2010-02-01 2012-01-16 Hospital For Sick Children Remote ischemic conditioning for treatment and prevention of restenosis
SG10201908570RA (en) 2010-03-31 2019-11-28 Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
WO2012024650A2 (en) 2010-08-19 2012-02-23 Abbott Laboratories Anti-ngf antibodies and their use
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
EP2826467B1 (de) 2010-12-22 2017-08-02 Purdue Pharma L.P. Gekapselte manipulationssichere Darreichungsformen mit gesteuerter Freisetzung
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
SG10201604040PA (en) 2011-05-20 2016-07-28 Alderbio Holdings Llc Anti-cgrp compositions and use thereof
CN104640856B (zh) 2012-05-11 2017-09-15 复位治疗公司 作为隐花色素调节剂的含有咔唑的磺酰胺类
JP6629069B2 (ja) 2012-06-06 2020-01-15 ゾエティス・エルエルシー イヌ化抗ｎｇｆ抗体およびその方法
CN105120846B (zh) 2013-02-05 2019-10-18 普渡制药公司 抗篡改的药物制剂
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
EP2968276A4 (de) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybride nekroptoseinhibitoren
KR20180037074A (ko) 2013-07-23 2018-04-10 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
GB201321731D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
WO2016177776A1 (en) 2015-05-04 2016-11-10 Academisch Medisch Centrum Biomarkers for the detection of aspirin insensitivity
CA3020839A1 (en) 2016-04-15 2017-10-19 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
MX2020009526A (es) 2018-03-12 2020-10-28 Zoetis Services Llc Anticuerpos anti-ngf y metodos de estos.
JP7309725B2 (ja) 2018-08-21 2023-07-18 杏林製薬株式会社 ２環性ヘテロ芳香環誘導体
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
CA3209491A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease
US20250215069A1 (en) 2021-08-27 2025-07-03 H. Lundbeck A/S Treatment of cluster headache using anti-cgrp antibodies
US20260001942A1 (en) 2024-06-21 2026-01-01 H. Lundbeck A/S Treatment of headache disorders and/or psychiatric symptoms using anti-cgrp antibodies, and compositions and methods related thereto

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064260A (en) * 1976-07-29 1977-12-20 E. I. Du Pont De Nemours And Company Anti-inflammatory diarylimidazothiazoles and their corresponding S-oxides
ZA775268B (en) * 1976-09-27 1978-07-26 Smithkline Corp Pharmacologically active compounds
US4263311A (en) * 1976-09-27 1981-04-21 Smithkline Corporation 5,6-Phenyl-2,3-dihydroimidazo [2,1-b] thiazoles
LU77703A1 (de) * 1977-07-07 1979-03-26 Ciba Geigy Ag Verfahren zur herstellung von bicyclischen thia-diaza-verbindungen
US4175127A (en) * 1978-09-27 1979-11-20 Smithkline Corporation Pyridyl substituted 2,3-dihydroimidazo[2,1-b]thiazoles
US4186205A (en) * 1979-01-08 1980-01-29 Smithkline Corporation 2,3-Di(4-substituted phenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazoles
US4636516A (en) * 1981-02-19 1987-01-13 Yamanouchi Pharmaceutical Co., Ltd. 3,5-di-tert-butyl-4-hydroxyphenyl-substituted heterocyclic compounds
ZW24186A1 (en) * 1985-12-12 1987-07-08 Smithkline Beckman Corp Inhibition of the 5-lipoxygenase pathway
US4794114A (en) * 1986-08-19 1988-12-27 Smithkline Beckman Corporation Inhibition of interleukin-1 production by monocytes and/or macrophages
JPH04506215A (ja) * 1989-06-13 1992-10-29 スミスクライン・ビーチャム・コーポレイション モノカイン活性干渉
WO1991000092A1 (en) * 1989-06-13 1991-01-10 Smithkline Beecham Corporation Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
AU8205991A (en) * 1990-06-12 1992-01-07 Smithkline Beecham Corporation Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases
ZA919797B (en) * 1990-12-13 1992-10-28 Smithkline Beecham Corp Bicyclo-5,6-dihydro-7h-pyrrolo-1,20-imidazol-7-ols and 7-ones
WO1992010190A1 (en) * 1990-12-13 1992-06-25 Smithkline Beecham Corporation Novel csaids

Also Published As

Publication number Publication date
US5552422A (en) 1996-09-03
DE69616749D1 (de) 2001-12-13
JPH11501902A (ja) 1999-02-16
ES2165969T3 (es) 2002-04-01
WO1996021667A1 (en) 1996-07-18
DE69616749T2 (de) 2002-08-01
EP0802917A1 (de) 1997-10-29
AU697650B2 (en) 1998-10-15
EP0802917B1 (de) 2001-11-07
AU4381496A (en) 1996-07-31
CA2209895A1 (en) 1996-07-18

Similar Documents

Publication Publication Date Title
DE69616749D1 (de) Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe
DE69514813D1 (en) Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren
PT828724E (pt) Diaril-5-oxigenadas-2-(5h)-furanonas comoinibidoras de cox-2
DE69529690D1 (de) Diaryl-2(5h)-fuaranone als cox-2-inhibitoren
CA2219115A1 (en) N-benzyl-3-indoleacetic acids as cyclooxygenase-2-inhibitors and antiinflammatory drugs
DE69825603D1 (de) 2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2
CA2260016A1 (en) Substituted pyridines as selective cyclooxygenase-2 inhibitors
YU54896A (sh) (methilsulfonil)fenil-2-(5h)-furanoni kao cox-2 inhibitori
UA48939C2 (uk) Дизаміщені фуранони, способи їх одержання, фармацевтична композиція на їх основі, спосіб лікування запального захворювання, проміжні сполуки
DE69825154D1 (de) Pyridazinone als inhibitoren von cyclooxygenase-2
BRPI0114344B8 (pt) composto retinóide, seu uso, sua composição farmacêutica e seu processo de preparação
RU94044454A (ru) Ингибитор аутоимунных заболеваний
DK0583421T3 (da) Substituerede dibenzoxazepinforbindelser, lægemidler og fremgangsmåder til anvendelse
CA2211320A1 (en) 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
PL328225A1 (en) Diphenylstilbenes as pro-medications used to produce cox-2-inhibitors
CA2301590A1 (en) 2-aminopyridines as inhibitors of cyclooxygenase-2
ATE239739T1 (de) Phospholipid-derivate von nichtsteroiden entzündungshemmenden medikamenten
CA2252401A1 (en) Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
CA2180624A1 (en) Diphenyl-1,2,3-thiadiazoles as anti-inflammatory agents
DE69434002D1 (de) 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis
ECSP972190A (es) Piridinas sustituidas como inhibidores selectivos de ciclooxigenasa 2